Abstract The modulation of cytoplasmic Ca 2+ concentration by release from internal stores through the inositol trisphosphate receptor (InsP 3 R) Ca 2+ release channel is a ubiquitous signaling system involved in the regulation of numerous processes. Because of its ubiquitous expression and roles in regulating diverse cell physiological processes, it is not surprising that the InsP 3 R has been implicated in a number of disease states. However, relatively few mutations in InsP 3 R genes have been identified to date. Here, I will discuss mutations in the type 1 InsP 3 R that have been discovered by analyses of human patients and mice with neurological disorders. In addition, I will highlight diseases caused by mutations in other genes, including Huntington's and Alzheimer's diseases and some spinocerebellar ataxias, where the mutant proteins have been found to exert strong influences on InsP 3 R function that may link InsP 3 R to disease pathogenesis.
Introduction
The modulation of [Ca 2+ ] i is a ubiquitous signaling system involved in the regulation of numerous processes, including transepithelial transport, learning and memory, muscle contraction, synaptic transmission, secretion, motility, membrane trafficking, excitability, gene expression, and cell division. Activation of phospholipases Cβ and Cγ by ligand interaction with G-protein-or tyrosine kinase-linked receptors, respectively, results in the hydrolysis of phosphatidlyinositol 4,5 bisphosphate, generating inositol 1,4,5-trisphosphate (InsP 3 ). InsP 3 binds to its receptor (InsP 3 R), a ligand-gated Ca 2+ release channel in the endoplasmic reticulum (ER). Analyses of InsP 3 -mediated [Ca 2+ ] i signals in single cells have revealed them to be unexpectedly complex. In the temporal domain, this complexity is manifested as repetitive spikes or oscillations, with frequencies often tuned to levels of stimulation, suggesting that [Ca 2+ ] i signals may be transduced by amplitude as well as frequency encoding. In the spatial domain, [Ca 2+ ] i signals may initiate at specific locations and remain highly localized or propagate as waves [2, 11] . Thus, InsP 3 -mediated [Ca 2+ ] i signals are often organized to provide different signals to discrete parts of the cell.
Three genes and alternatively spliced isoforms have identified a family of InsP 3 Rs in mammalian cells, including humans [15] . The three full-length sequences are 60-80% homologous. The InsP 3 R is ubiquitously expressed, perhaps in all cell types [15, 68] . The isoforms have distinct and overlapping patterns of expression with most cells expressing more than one, and expression levels can be modified during differentiation and by usedependent degradation [15] . This impressive diversity of expression suggests that cells require distinct InsP 3 Rs to regulate specific functions. Nevertheless, the functional implications of this diversity, at the single channel, cellular, and organ level, remain largely unappreciated.
The InsP 3 Rs are ∼2,700-2,800 amino acid intracellular membrane proteins that exist as homo-or hetero-tetramers [15, 32] . Structurally, the proteins contain a cytoplasmic Nterminus comprising ∼85% of the protein, a hydrophobic region predicted to contain six membrane-spanning helices, and a relatively short cytoplasmic C-terminus (Fig. 1a) . Functionally, the N-terminal domain can be divided into one comprising an N-terminal InsP 3 binding domain and a more distal 'regulatory'/'coupling' domain (Fig. 1b) . InsP 3 binding to the InsP 3 R is stoichiometric and localized by mutagenesis and an X-ray structure to a region within residues 226-578 [5, 80, 81] . The InsP 3 R is itself a ligandgated ion channel. The basic six-transmembrane (TM)-A B Fig. 1 Structural determinants of the InsP 3 R. a Overall domain structure. The InsP 3 R molecule depicted as a linear amino acid sequence, with the amino terminal InsP 3 binding region (red), coupling region (yellow), transmembrane region (green), and carboxyl tail (blue) depicted. b Linear amino acid sequence. Residues are numbered according to the rat type 1 SI+, SII+, SIII-sequence (protein accession number 121838). The structural features shown are: Arm sub-domain and β-trefoil in the InsP 3 -binding suppressor domain; β-trefoil and armadillo repeats in InsP 3 binding core-domain; armadillo repeats in the coupling/regulatory domain; alternative splicing regions SI, SII, and SIII for type 1 InsP 3 R; opt deletion in type 1 InsP 3 R mutant; Δ18 deletion in type 1 InsP 3 R; ATP-binding site ATPA; transmembrane helices TM1-6, and pore-forming P region with selectivity filter; dimerizing region; tetramer forming region; S1589 and S1755 are PKA/PKG phosphorylation sites; mutation of Pro1059 to Leu in type 1 InsP 3 R associated with SCA15; mutation of Val494 to Ile in type 1 InsP 3 R associated with SCA15. The sequences involved in the interaction of InsP 3 R channel with the following proteins are also depicted: CaBP1; IRBIT; CIB1; Na [15] with permission from the American Physiological Society domain topology of InsP 3 Rs is shared with other cation channels (Fig. 2) . By analogy, putative TM helices 5 and 6 and the intervening intra-luminal loop likely constitute the permeation pathway [4, 53] . Binding of InsP 3 gates the channel open, modulated by the linker region that contains consensus sequences for phosphorylation, proteolytic cleavage, and binding by proteins and ATP that integrate other signaling pathways or metabolic states with the function of the InsP 3 R.
Because of its ubiquitous expression and roles in regulating diverse cell physiological processes in so many cell types, it is perhaps not surprising that the InsP 3 R has been implicated in a number of disease states, including polycystic kidney disease [41] , cholestasis [55] , cardiac arrythmias [36] , and inflammation [51] among others. It is surprising, however, that relatively few mutations in InsP 3 R genes have been identified to date. Many disease-causing mutations have been discovered in the other major and related family of intracellular Ca 2+ release. It seems likely that the relative dearth of identified disease-causing InsP 3 R mutations reflects a widespread functional redundancy of multiple InsP 3 R isoforms expressed in most cells. In this review, I will discuss mutations in the type 1 InsP 3 R that have been discovered by analyses of human patients and mice with neurological disorders. In addition, I will highlight diseases caused by mutations in other genes, including Huntington's and Alzheimer's diseases (ADs) and some spinocerebellar ataxias (SCAs), where the mutant proteins have been found to exert strong influences on InsP 3 R function that may link InsP 3 R to disease pathogenesis.
Role of InsP 3 R in spinocerebellar ataxias 15 and 16
To date, the only known diseases that have been definitively linked to a mutation(s) in an InsP 3 R gene are spinocerebellar ataxias 15 and 16. The SCAs are a heterogeneous group of genetic disorders with clinically distinct features. Both SCA15 and SCA16 are uncommon, autosomal, dominant, pure cerebellar ataxias with adult onset, slow progression, and pronounced cerebellar atrophy. Heterozygous deletions of the 5′ part of the type 1 InsP 3 R gene, encompassing exons 1-10, 1-40, and 1-44 (of 59 exons), were identified in three human SCA15 families [73] and a heterozygous complete deletion of the gene was found in another [21] . Heterozygous deletion of exons 1-48 was identified in an individual affected by SCA16 [30] . That the diseases were associated with mutations in the type 1 channel isoform is consistent with the high level of InsP 3 R-1 protein expression in the cerebellum, particularly in the Purkinje neurons [16, 44, 47] . SCA15 was linked to a complete deletion of the InsP 3 R-1 [21] , and SCA16 revealed deletions in the InsP 3 R-1 gene only, without involvement of the adjacent SUMF1 gene [30] , demonstrating that the diseases are caused by InsP 3 R-1 loss of function. Western blot analysis of immortalized lymphoblasts from SCA15-affected family members with exons 1-10 deleted had strongly reduced InsP 3 R-1 expression [73] . Haplo-insufficiency of InsP 3 R-1 may account for the delayed onset and slow progression of the disease. In contrast, knockout of the mouse InsP 3 R-1 results in ataxia and seizures within a couple of weeks of birth, with death by 4 weeks of age [46] . The absence of epilepsy or reduced life span in the SCA15 and SCA16 patients may suggest that the InsP 3 R-1 expression from one allele provides a protection against a more severe phenotype. In agreement, heterozygote InsP 3 R-1 knockout mice suffer only from some defects in motor coordination [50] .
Two heterozygous missense mutations in InsP 3 R-1 have also been identified in SCA15-affected individuals. In one family, patients had valine at position 494 in the amino acid sequence replaced by isoleucine (V494I) [17] . This residue is located within the InsP 3 binding domain (Fig. 1b) . The core InsP 3 binding domain consists of a proximal β-trefoil domain linked to an α-helical-rich armadillo repeat domain. InsP 3 binding is coordinated by residues contributed by both domains [5, 15] . Val494 is located in the armadillo repeat domain at the end of a loop that connects the first two alpha helices. It is located far from the InsP 3 R binding pocket, and it is not particularly conserved among species. In the Xenopus InsP 3 R-1, the residue is an isoleucine. Thus, an association of the disease with the V494I mutation in SCA15 patients is perhaps surprising. Based on the gene deletion phenotypes, if the mutation is indeed responsible for the SCA15 disease, it must represent a loss of function. This region of the protein also binds proteins, including CaBP1 [77, 79] , CIB1 [77] , and IRBIT [1] (Fig. 1b) , although the role of this particular residue in their interactions with the InsP 3 R has not been studied.
In another family, patients had proline at position 1059 in the amino acid sequence replaced by leucine (P1059L; (21) ). The proline is conserved in type 1 InsP 3 R isoforms among species, although it is alanine in the human types 2 and 3 isoforms. Nothing is known regarding the role of this residue in the ion channel function of the InsP 3 R-1. This residue is localized in the coupling domain (Fig. 1b) , with the surrounding region not known to be involved in protein interactions. It is possible that the missense mutation does not cause disease, although this was felt to be unlikely [21] . Again, if the mutation is indeed responsible for the SCA15 disease, it must represent a loss of function. In a preliminary report, expression of recombinant rat InsP 3 R-1 containing the corresponding mutation formed a functional channel [49] . As discussed below, an InsP 3 R-1 mutation in the opistotonus (opt) mouse is phenotypically equivalent to that of the knockout [57] , whereas the recombinant channel is functional [70] . Thus, the mechanisms that account for the loss-of-function phenotype remain to be determined.
InsP 3 R mutant mice
The opt mouse
The opistotonus mouse was identified as having a naturally occurring deletion of exons 43 and 44 in the type 1 InsP 3 R channel that results in an in-frame deletion of residues 1732-1839 in the regulatory domain immediately after the SII splice region [57] (Fig. 1b) . The phenotype of the homozygous opt mouse is similar to that of the type 1 InsP 3 R homozygous knock-out mouse. Both mice are smaller than their normal littermates at birth, lack normal locomotor behaviors, display seizures at about 2 weeks of life, and then die by 3-4 weeks of age [46, 57] . Metabotropic glutamate receptor-mediated Ca 2+ release was only moderately diminished in Purkinje cell soma in P4 cerebellar slices from homozygous opt mice [57] . A reconstituted recombinant opt InsP 3 R-1 was functional, although it had apparent diminished ATP sensitivity compared with wild-type (WT) channels [70] . The optdeleted region of the InsP 3 R contains a putative ATP binding site (Fig. 1b) that may account for reduced ATP responsiveness, and it also contains a PKA phosphorylation site. The mutant protein is expressed at lower levels than the wild-type protein [57] . We have confirmed that InsP 3 R-1 protein level is reduced by ∼50% in the heterozygote opt brain and is nearly undetectable in brain lysates from homozygous opt mice (our unpublished results). It seems most likely that the major deficit in opt mice is reduced InsP 3 R-1 protein expression, consistent with the nearly identical phenotypes of opt and InsP 3 R-1 knock-out mice. However, the Ca 2+ imaging results may not be easily reconciled with this conclusion. The mechanisms that account for the reduced channel expression are unknown. The fact that the recombinant channel behaves relatively normally suggests that the 108-residue deletion does not prevent normal oligomerization, ligand binding, permeation, or gating. Persistent activation of Gαq induces downregulation of InsP 3 R protein levels in some cells [78] . However, the published single channel studies do not indicate that the opt channel is hyper-active, suggesting that this mechanism is not responsible. It is possible that cellular quality control mechanisms recognize the channel as defective and quickly degrade it.
The Δ18 mouse
The Δ18 mouse was identified as having an in-frame deletion of 18 base pairs within exon 36 of InsP 3 R-1 that results in the deletion of six residues (residues 1533-1538; Glu-Ser-Cys-Ile-Arg-Val) in the regulatory domain [73] (Fig. 1b) . It was observed as a severe autosomal recessive progressive movement disorder, with a survival time of approximately 4 weeks, phenotypes reminiscent of both InsP 3 R-1 knock-out and opt mice. The six residues are not particularly conserved across the three channel isoforms and species, although the Cys and a basic amino acid 2 residue downstream appear to be. The functional significance of these residues is unknown. In a preliminary study, it was reported that the recombinant rat channel with the six-residue deletion formed a functional channel [49] . Nevertheless, as in the opt mouse, the deletion appears to be associated with a pronounced reduction of InsP 3 R-1 protein levels, measured by immunostaining in cerebellar Purkinje neurons and Western blotting of whole brain lysates [73] . It is likely therefore that the disease phenotype is caused by a lack of InsP 3 R-1 protein expression as a consequence of the deletion.
Hints of defective InsP 3 R roles in other ataxias

CA8
A homozygous mutation in the CA8 gene was discovered in a consanguineous family as the cause of a syndrome of ataxia and mild mental retardation and ambulation on all four extremities (quadrupedal gait) [72] . CA8 encodes for the carbonic anhydrase-related protein VIII, a catalytically inactive carbonic anhydrase with strong expression in cerebellar Purkinje neurons. In affected humans, serine at position 298 was replaced by proline. In cell culture, the mutation resulted in severely reduced CA8 protein expression, which was in part restored by inhibition of the proteasome [72] . It was therefore speculated that the mutation destabilizes the protein and causes disease as a result of a loss of CA8 function. Loss of function of CA8 was previously identified as the autosomal recessive deficit in the waddles (wdl) mouse [31] , a spontaneous model that has a 19-base-pair deletion in CA8 that results in a lack of mRNA and protein in the homozygote. Thus, it, too, is a CA8 loss of function. The mouse has ataxia and appendicular dystonia that produces nearly straight limbs and a "waddling" side-to-side gait during ambulation [31] . Homozygous mice have normal gross cerebellar morphology with abnormalities of parallel fiber-Purkinje cell synapses and defects in excitatory transmission [24] .
The only reported function of CA8 is to inhibit InsP 3 binding to the InsP 3 R-1 [26] . CA8 was discovered in a yeast two-hybrid screen as an interactor with the regulatory domain of the channel within residues 1387-1647 (Fig. 1b) . CA8 and InsP 3 R-1 co-localized extensively in isolated cerebellar Purkinje cells. Binding of CA8 reduced the apparent affinity of the channel for [ 3 H]InsP 3 binding [26] . Since the binding region is distinct from the InsP 3 binding domain, this reflects an allosteric effect, suggesting that CA8 binding induces conformational changes in the protein. However, nothing else is known regarding the functional consequences of CA8 binding to the InsP 3 R or whether the binding is related to the phenotypes described above. Lack of interaction of CA8 with the InsP 3 R in the CA8 patients or wdl mice would not be expected, a priori, to result in loss of InsP 3 R function. As discussed below, polyglutamine-expanded huntingtin and ataxins 1 and 2, the latter that result in cerebellar ataxias, all bind to the InsP 3 R and enhance its sensitivity to InsP 3 . Furthermore, mutant presenilins that cause Alzheimer's disease bind to the InsP 3 R and increase its activity (below). It is conceivable therefore that InsP 3 R-1 is more sensitive to InsP 3 in CA8 patients and wdl mice, and that the disease is a result of gain of function of the channel. Further studies are necessary to establish a role of the InsP 3 R in CA8 patients and wdl mice.
Spinocerebellar ataxias 2 and 3
Abnormal Ca 2+ release through the InsP 3 R has been implicated in two spinocerebellar ataxias in addition to SCAs 15 and 16. Following their observations of the interaction of mutant huntingtin protein with the carboxyl terminus of the InsP 3 R-1 (below), the Bezprozvanny group explored whether other disease-causing polyglutamine repeat proteins similarly bind there and affect the channel activity [8, 42] . SCA2 and SCA3 are caused by polyglutamine expansions in ataxin2 and ataxin3, respectively [35, 38] . It was discovered in pulldown and co-immunoprecipitation assays that the polyglutamine expanded forms, but not the normal proteins, and each interacted with the same region of the InsP 3 R-1 carboxyl terminus (residues 2627-2749) [8, 42] (Fig. 1b) . To explore the functional consequences of these interactions, either the wild-type or mutant ataxin proteins were co-expressed with rat InsP 3 R-1 in Sf9 cells, and microsomes purified from the infected cells were reconstituted into lipid planar bilayers. In each case, reconstituted channels from the cells expressing the mutant ataxins were more sensitive to activation by lower concentrations of InsP 3 . In cells in culture, medium spiny neurons in the case of SCA2 and Purkinje neurons in the case of SCA3, metabotropic glutamate receptor stimulation caused higher-peak cytoplasmic Ca 2+ responses in cells from the mutant mice. It was speculated that these Ca 2+ responses may underlie cellular toxicity because enhanced cell death induced by prolonged glutamate exposure in the disease neurons was diminished by treatment with dantrolene, a RyR Ca 2+ release channel inhibitor. It was suggested that dantrolene provided this protection by inhibiting Ca 2+ signals that emanate from InsP 3 -induced Ca 2+ release that is amplified by CICR by the RyR. Dantrolene feeding provided protection against age-dependent disease-associated morphological and behavioral deficits. The authors concluded that abnormal neuronal Ca 2+ signaling through the InsP 3 R-1 may play a role in the pathogenesis of many polyglutamine expansion disorders [8, 42] .
The role of InsP 3 R in Huntington's disease
Huntington's disease (HD) is a dominantly inherited neurodegenerative disorder caused by amino-terminal polyglutamine expansions in huntingtin (Htt), a large ubiquitously expressed protein [20, 75, 82] . The disease is associated with movement disorders, cognitive decline, and psychiatric symptoms that progress over 15-20 years before death. Brain neurons in HD have characteristic cytoplasmic and nuclear aggregates containing htt and other proteins [82] . HD pathogenesis is due to a toxic gain of function of mutant htt that results in neuronal loss in the cortex and striatum, although the molecular mechanisms that underlie pathogenesis and the selective vulnerability of particular neuronal populations are still debated on [69, 75, 82] . The physiological function of wild-type htt is unknown. Its sequence indicates that it possesses many HEAT repeats, protein interaction domains that suggest that it may serve as a molecular scaffold [43] .
The type 1 InsP 3 R was identified in a comprehensive screen of protein interactors with htt [33] . Importantly, it behaved as a genetic modifier of HD-associated neurodegeneration. In a Drosophila model, in which a polyglutamine-expanded human Htt transgene expression in the eye caused retinal degeneration, InsP 3 R expression modified the eye phenotype: reduced expression of the channel suppressed it, whereas enhanced expression made it more severe [33] . In a separate screen, huntingtin-associated protein 1 (HAP1), a protein that also interacts with Htt, particularly the polyglutamine expanded forms (Htt exp ) [13] , was also identified to interact with InsP 3 R-1. The interaction was with the carboxyl terminus of the channel within residues 2627-2736 [65] (Fig. 1b) . This channel construct also directly bound to Htt exp and to a lesser extent to Htt. Both interactions were strengthened by the presence of HAP1, suggesting that the three proteins might exist in a complex [65] . Whereas the addition of recombinant HAP1 to the cytoplasmic aspect of reconstituted InsP 3 [64] .
Expression in vitro of a GFP-fused carboxyl-terminal interacting region in medium spiny neurons from an HD transgenic mouse normalized exaggerated cytoplasmic Ca 2+ responses to glutaminergic stimulation and provided protection from glutamate excitotoxicity [63] . Long-term expression of the construct in the striatum of virally injected mice reduced the biochemical interaction of InsP 3 R-1 and htt exp and reduced motor coordination deficits and loss of medium spiny neurons. Remarkably, the fusion protein also reduced the load of aggregated Htt exp [63] . Although many questions remain, these studies indicate a strong involvement of the InsP 3 R in HD pathogenesis and suggest novel therapeutic targets and strategies. The role of InsP 3 R in Alzheimer's disease Alzheimer's disease is a common form of dementia involving slowly developing and ultimately fatal neurodegeneration. The etiology of AD is debated on, with age being the main risk factor but with major molecular mechanisms remaining unclear. A hallmark feature of AD is accumulation of extracellular β amyloid (Aβ) plaques, intracellular neurofibrillary tangles, and neuronal loss [14] . Mutations in presenilins (PS1 and PS2) and amyloid precursor protein (APP) cause most early-onset, autosomal dominant familial cases of the disease (FAD) [67] . Presenilins are components of a protein complex that proteolytically processes APP into Aβ peptides [54] . In the "amyloid hypothesis" of AD, an accumulation of Aβ due to defective processing and clearance leads to patho- From [10] with permission from Elsevier logical sequelae associated with the disease [22] . The identification of three components in FAD-PS1, PS2, and APP-that are linked in a biochemical pathway that impinges on Aβ production has strongly influenced the acceptance of the amyloid hypothesis [22] . Nevertheless, much evidence suggests that altered Ca 2+ signaling is associated with expression of FAD mutant PS in symptomatic or pre-symptomatic patient cells and in brain neurons in AD mouse models long before the appearances of plaques or tangles and in a variety of heterologous expression systems [3, 19, 37, 61] . Before the molecular identification of PS, it was shown that fibroblast lines from AD patients (later shown to harbor a FAD mutation in PS1) generated exaggerated [Ca 2+ ] i responses to sub-maximal concentrations of two G-protein coupled receptor agonists that activate PLC [29] . Subsequent studies have confirmed that FAD PS expression is associated with an exaggerated ER Ca 2+ release in several cell systems. However, these studies have not led to consensus regarding the molecular mechanisms involved (reviewed in 37, 58] . Exaggerated ER Ca 2+ release has been ascribed to the enhanced loading of the ER lumen [58] due either to enhanced SERCA Ca 2+ pump activity [18] or to disruption of a putative Ca 2+ channel function of wild-type PS [48, 71] . Alternately, exaggerated Ca 2+ release has been accounted for by enhanced Ca 2+ liberation from normal stores through InsP 3 R [40, 58] or RyR [6, 56, 60] Ca 2+ release channels, both in vivo [6, 56, 59, 60] and in vitro [12, 25, 29, 39] , either as a consequence of enhanced channel expression [6, 7, 34, 61] or, in the case of the InsP 3 R, of enhanced activity in response to its ligand InsP 3 [10, 29] .
A biochemical interaction of WT and FAD mutant PS1 and 2 with the InsP 3 R was identified. Functionally, FAD PS specifically had gain-of-function consequences for the activity of the channel, which in turn was associated with exaggerated Ca 2+ signaling in intact cells [9, 10] . An example is shown in (Fig. 3) . FAD and WT-PS1 were expressed in insect Sf9 cells, and patch clamp experiments were performed on isolated nuclei to record InsP 3 R ion channels in their native membrane [45] . The InsP 3 and Ca 2+ regulation of the Sf9 channel, the type 1 isoform, is similar to the dominant neuronal type in the mammalian brain [27] . In conditions optimal for channel activity, InsP 3 R channels in control nuclei had a high P o (Fig. 3b) . In nuclei from either M146L-PS1 or WT-PS1-expressing cells, no novel ion channels were detected (Fig. 3a) , nor were channels observed in the absence of InsP 3 (Fig. 3a) or in the presence of InsP 3 and its competitive inhibitor heparin. Activated Each section consists of a set of four traces of the same single channel current record: (top) unprocessed current trace, (second) idealized current trace generated using Qub software (third), idealized current trace after burst analysis (closing events <10 ms were filtered), and (bottom) modal assignment by analyzing channel burst (t b ) and gap (t g ) durations [28] . In EVER1-infected cells, low P o is associated with prevalence of L gating mode. In PS1-M146L infected cells, enhanced P o is manifested by increased t b and decreased t g . Channel occupancy of H mode is dominant, whereas occupancy of L gating mode is significantly decreased. From [9] with permission from the American Association for the Advancement of Science InsP 3 R channels in WT-PS1-infected cells had P o similar to control cells, whereas P o was elevated significantly in FAD M146L-PS1-infected cells (Fig. 3b, d) (Fig. 3c, d) . Similar results were obtained with an FAD PS2 mutant (N141I) [9, 10] .
Enhanced InsP 3 R channel activity appears to be a conserved feature of FAD PS-expressing cells, since similar results were observed in cells expressing other FAD mutant PS [9] . γ-Secretase-dead mutants also significantly enhanced the InsP 3 R channel activity, although to a lesser extent than the FAD mutants, indicating that the secretase activity of PS is not required for its effects on InsP 3 R gating [9] . Interestingly, the P o of channels recorded from cells infected with frontotemporal dementia-associated mutant PS1 was not different from controls [9] . Thus, several FAD-mutant PS have similar effects on InsP 3 R gating, and these effects appear not to be recapitulated in PS mutants associated with a different neurological disease.
These effects of FAD PS on InsP 3 R gating appear to be remarkably robust, since they have now been observed in five different cellular systems: Sf9 cells, chicken DT40 B cells, human FAD patient B cell-derived lymphoblasts and fibroblasts, and neurons from FAD-PS AD mice, in the absence of and preceding disease pathology [9, 10] . The strikingly similar effects of mutant PS expression of InsP 3 R channels in such diverse cellular systems from different species suggest that the effects of mutant PS on channel activity is a robust one in all cell types and InsP 3 R isoforms. The results at the single-channel level are consistent with the observations of exaggerated InsP 3 -mediated [Ca 2+ ] i signals in FAD patient fibroblasts [29] and other cells with mutant PS expressed. An example in DT40 B cells, where the electrophysiological effects of FAD PS have been demonstrated [10] , is shown in Fig. 4 (Fig. 4c, d ), due to periodic release from ER through InsP 3 R, because they are absent in DT40-KO cells in which all three isoforms of the InsP 3 R were genetically deleted [62] [76] . In cells expressing FAD PS1, oscillation frequency and number of cells responding was increased, and the latency between application of agonist and first response decreased (Fig. 4e, f) . In a subset (30%) of cells expressing M146L-PS1, the latency was nearly abolished (Fig. 4c, d, f) , a response that was reminiscent of that of normal cells to strong stimulation [76] . These effects demonstrate that FAD PS1 generates exaggerated InsP 3 Rmediated [Ca 2+ ] i responses, as observed in other cell types, and they suggest, consistent with the single channel studies, that FAD PS expression enhances InsP 3 R sensitivity to InsP 3 .
The electrophysiological studies suggest that FAD PS stimulate InsP 3 R gating by a mechanism that involves From [10] with permission from Elsevier PS-mediated effective sensitization of the channel to InsP 3 , most likely through an allosteric mechanism. Nevertheless, this conclusion is somewhat tentative, as are those regarding of the effects of polyglutamineexpanded protein interaction effects on InsP 3 [23] and Aβ production [19, 52] which, together with mutant PS-enhanced production of amyloidogenic Aβ, results in plaque formation. From [9] with permission from the American Association for the Advancement of Science terized by fast channel openings and closings and a low P o L mode is characterized by long closings with brief openings. In nuclei isolated from control cells expressing an irrelevant protein or from Sf9 cells infected with WT-PS1 or PS2, similar modal distributions were observed (Fig. 5 ). In contrast, the H mode was the dominant gating mode of InsP 3 R recorded from FAD PS-expressing cells (Fig. 5) [52] , features associated with AD. The possible role of InsP 3 R in Aβ production was examined in DT40 cells that were engineered to stably express APP harboring Swedish mutations (APP SWE ) that enhance Aβ production, together with either PS1-WT or PS1-M146L (Fig. 6, top) . PS1-M146L specifically enhanced Aβ 40 and Aβ 42 secretion by approximately two and threefold, respectively, compared with control cells. Of note, the Aβ 42 /Aβ 40 ratio was enhanced in mutant PS1-expressing cells (Fig. 6 ), as observed in AD patients. To determine the role of the InsP 3 R in PS1-dependent APP processing, APP and PS1-expressing cells were generated in the DT40 cells that lacked expression of InsP 3 R (InsP 3 R-KO). Notably, mutant PS1 enhancement of Aβ secretion observed in InsP 3 R-expressing cells was abolished. Furthermore, the absolute levels of Aβ peptides detected were strongly reduced in all control and PS1-expressing InsP 3 R-KO lines (Fig. 6, bottom) . These results suggest that APP processing by FAD PS1 has a strong dependence on InsP 3 R activity (Fig. 7) .
Conclusions
Human and mouse genetics have provided the strongest evidence that InsP 3 R mutations can result in disease. However, the number of mutations and diseases identified are limited. To date, only one channel isoform, the type 1, has been implicated in these studies. Furthermore, the diseases have all been neurological and predominantly cerebellar. Cerebellar Purkinje neurons, with the highest InsP 3 R-1 protein expression levels in the body, are the final integrators of sensory inputs and provide cerebellar cortex outputs that control motor coordination. The genetics has suggested that the lack of two functional InsP 3 R-1 alleles disrupts cerebellar function. It is interesting that the recombinant expression of several of the InsP 3 R-1 mutant proteins produces functional ion channels, including opt, Δ18, and P1059L, but appear to cause a disease due to diminished expression, perhaps due to rapid degradation by cellular quality control mechanisms. It will be interesting, in future studies, to examine the effects of these mutations not only on ion channel properties but also on the kinetics of channel biogenesis and turnover. RyR1 and RyR2 are the predominant RyR isoforms in skeletal and cardiac muscle, respectively. Many mutations in these isoforms have been identified because of the pronounced muscle phenotypes they cause. The reliance in the cerebellum on one particular InsP 3 R isoform seems to be the exception in the human body. It seems likely that most cell types and tissues have functional InsP 3 R redundancy that renders InsP 3 R mutations phenotypically non-penetrant. Nevertheless, it seems likely that other diseases will be discovered that have mutations in InsP 3 R genes as their basis. A recent genomewide association study linked an intronic single nucleotide polymorphism in the InsP 3 R-2 gene to risk of amyotrophic lateral sclerosis, a motor neuron disease [74] .
